N-linked glycosylation and its impact on the electrophoretic mobility and function of the human proton-coupled folate transporter (HsPCFT)  by Selcuk Unal, Ersin et al.
Biochimica et Biophysica Acta 1778 (2008) 1407–1414
Contents lists available at ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r.com/ locate /bbamemN-linked glycosylation and its impact on the electrophoretic mobility and function of
the human proton-coupled folate transporter (HsPCFT)☆
Ersin Selcuk Unal b, Rongbao Zhao a,b, Andong Qiu a,b, I. David Goldman a,b,⁎
a Department of Medicine, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461, USA
b Department of Molecular Pharmacology, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461, USAa r t i c l e i n f o☆ Data in this paper are from Ersin S. Unal's thes
fulﬁllment of the requirements for the Degree of Doctor
Division of Medical Sciences, Albert Einstein College of
This work was supported by a grant from the National In
⁎ Corresponding author. Cancer Center, Albert Einst
Morris Park Avenue, Bronx, NY 10461, USA.
E-mail address: igoldman@aecom.yu.edu (I.D. Goldm
Abbreviations: RFC, reduced folate carrier; PCFT, prot
SLC, solute carrier family; TMDs, transmembrane dom
acetyl-β-D-glucosaminyl)asparagine amidase F; Endo H
dase H; MTX, methotrexate; DTT, dithiothreitol; SDS-
polyacrylamide gel electrophoresis; OMIM, Online Men
0005-2736/$ – see front matter © 2008 Elsevier B.V. Al
doi:10.1016/j.bbamem.2008.03.009a b s t r a c tArticle history:
Received 19 September 2007
Received in revised form 7 March 2008
Accepted 7 March 2008
Available online 20 March 2008The human proton-coupled folate transporter (HsPCFT, SLC46A1) mediates intestinal absorption of folates and
transport of folates into the liver, brain and other tissues. On Western blot, HsPCFT migrates as a broad band
(~55 kDa), higher than predicted (~50 kDa) in cell lines. Western blot analysis required that membrane
preparations not be incubated in the loading buffer above 50 °C to avoid aggregation of the protein. Treatment
of membrane fractions from HsPCFT-transfected HeLa cells with peptidyl N-glycanase F, or cells with
tunicamycin, resulted in conversion to a ~35 kDa species. Substitution of asparagine residues of two canonical
glycosylation sites to glutamine, individually, yielded a ~47 kDa protein; substitution of both sites gave a
smaller (~35 kDa) protein. Single mutants retained full transport activity; the double mutant retained a
majority of activity. Transport function and molecular size were unchanged when the double mutant was
hemagglutinin (HA) tagged at either the NH2 or COOH terminus and probed with an anti-HA antibody
excluding degradation of the deglycosylated protein. Wild-type or deglycosylated HsPCFT HA, tagged at
amino or carboxyl termini, could only be visualized on the plasma membrane when HeLa cells were ﬁrst
permeabilized, consistent with the intracellular location of these domains.
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SLC46A11. Introduction
Mammals meet their biosynthetic needs for one carbon donors by
absorbing dietary folates in the acidic microclimate at the brush-
border membrane of the upper small intestine [1]. Polyglutamate
derivatives of 5-methyltetrahydrofolate constitute more than 90% of
folate nutrients [2]. Prior to absorption, these congeners are hydro-
lyzed by gamma-carboxypeptidase to the monoglutamate which is
the major blood folate [3]. Until recently, the reduced folate carrier
(RFC, SLC19A1), which is expressed at the apical brush-border mem-
brane along the entire intestine [4,5], was considered to represent the
mechanism by which folates are absorbed [6] despite the fact that the
absorptive mechanism was known to have a different pH optimum
and structural speciﬁcity [7]. Recently, a novel folate transporteris to be submitted in partial
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l rights reserved.(PCFT) was identiﬁed that recapitulates the properties of intestinal
folate absorption [8]. Conﬁrmation that this transporter is required for
intestinal folate absorption came from the observation that loss-of-
function mutations in HsPCFT are the genetic basis for hereditary
folate malabsorption (HFM) (OMIM 229050) [8,9], an autosomal
recessive disorder characterized by defects in both intestinal folate
absorption and folate transport into the central nervous system [10].
Besides the small intestine, HsPCFT mRNA is expressed in kidney,
liver, placenta, and to a lesser extent in other tissues [8]. Likewise, a low-
pH folate transport activity, now attributed to PCFT, has been
demonstrated in the intestine [1,11], liver [12], kidney [13], and in
human solid tumor cell lines [14,15]. HsPCFT mediated folate transport
can be distinguished from RFC mediated transport: (i) the former has a
low-pH optimum (~5.5) while RFC has a pH optima of ~7.4. (ii) HsPCFT
has a high afﬁnity for folic acid and other folates (Km's range from 0.5 to
1 μM) at low pH which decreases as the pH is increased. RFC has a very
low afﬁnity for folic acid (Ki~200 μM) which, along with its afﬁnity for
other folates/antifolates, is largely pH-independent over a pH range of
5.5 to 7.4 [16]. RFC has a very high afﬁnity (Ki~0.2 μM) for PT523;HsPCFT
has a very low afﬁnity (N50 µM) for this antifolate [8,17].
HsPCFT protein has been detected at different molecular sizes in
cell lines and species, attributed to post-translational modiﬁcation,
most likely by N-linked glycosylation [8]. Although the Asn-Xaa-Ser/
Thr signals or sequons are present in the HsPCFT sequence (N58, N68),
not all sequons are glycosylated due either to the effects of
neighboring amino acid residues or their intra- versus extracellular
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which HsPCFT is, in fact, glycosylated and the impact of glycosylation
on the electrophoretic properties of the protein and its transport
function.
2. Materials and methods
2.1. Chemicals
Tritiated methotrexate (MTX-disodium salt, [3′, 5′, 7-[3H](N)]) (Catalog number
MT701) was obtained from Moravek Biochemicals Inc. (Brea, CA), puriﬁed by liquid
chromatography, and maintained as previously described [20]. PNGaseF (peptide-N4-
(N-acetyl-β-D-glucosaminyl)asparagine amidase F) (G5166) and tunicamycin from
Streptomyces species (T7765) were obtained from Sigma (St. Louis, MI). Protease
inhibitor cocktail (Cat# 11836170001) was obtained from Roche Applied Science
(Mannheim, Germany).
2.2. Site-directed mutagenesis
Site-directed mutagenesis was carried out according to the QuikChange II XL
protocol from Strategene (La Jolla, CA). Wild-type HsPCFT cDNA cloned into the BamHI
site of the mammalian expression vector pcDNA3.1(+) was used as the template [8].
Two complementary forward and reverse primers, which carry the targeted nucleotide
changes in the middle region, were designed individually for introducing glutamines
into HsPCFT primary sequence at positions 58, 68 and 58/68 [Table 1]. After initial
denaturation at 95 °C for 1min, the targeted vectors were generated for 18 cycles of 50 s
at 95 °C for denaturation, 50 s at 60 °C for annealing, 16 min at 68 °C for extension
followed by a ﬁnal extension period of 7 min at 68 °C. DpnI (10 U/µL) restriction enzyme
was used to digest the parental dsDNA. The mixture (3 µL) was transformed into Top10
ultra competent cells (Invitrogen). Plasmids carrying the desired mutations were
identiﬁed by DNA automated sequencing in the Albert Einstein Cancer Center Genomics
Shared Resource. The entire coding region of HsPCFT was sequenced to conﬁrm the
absence of any other polymerase introduced mutations.
2.3. Epitope tagging
A hemagglutinin (HA) peptide epitope (YPYDVPDYA) was fused to the wild-type
and N58Q/N58Q-HsPCFT by PCR-based site-directed mutagenesis using the primers
listed in Table 1. A BglII restriction site was included in the upstream N-terminal HA tag
primer sequence for subcloning. The PCR product was puriﬁed, digested with BglII, and
ligated into BamHI-digested HsPCFT in pcDNA3.1(−) to generate the N-HA-HsPCFT and
N-HA-N58Q/N68Q-HsPCFT. The downstream primer used for introducing the C-
terminal HA epitope contained an XbaI restriction site. The upstream primer included
a HindIII restriction site. The PCR product was puriﬁed, digested with HindIII and XbaI,
and ligated into HindIII–XbaI digested HsPCFT in pcDNA3.1(+) to generate the C-HA-
HsPCFT and C-HA-N58Q/N68Q-HsPCFT. The ligation products were transformed into
Top10 ultra competent cells (Invitrogen). Plasmids carrying the HA tags were identiﬁed
by DNA automated sequencing.
2.4. Cell culture and transfection
HeLa cells, originally obtained from the American Type Tissue Collection (Manassas,
VA), have been maintained in this laboratory in RPMI-1640 medium supplemented
with 10% fetal bovine serum, 100 U/mL penicillin and 100 µg/mL streptomycin at 37 °C
in a humidiﬁed atmosphere of 5% CO2. Lipofectamine 2000 (Invitrogen) was used
according to the manufacturer's protocol for transient transfection of plasmid DNA into
these cells. To create stably transfected HeLa cell lines, transiently transfected cells wereTable 1
Primers for site-directed mutagenesis and PCR primers for N- and C-terminal HA-
epitope insertions for wild-type and N58Q/N68Q-HsPCFT
Primer sequence (5′ to 3′)
N58Q Forward GCCGACCTCGGCTACCAAGGCACCCGCCAAAGG
Reverse CCTTTGGCGGGTGCCTTGGTAGCCGAGGTCGGC
N68Q Forward AGGGGGGGCTGCAGCCAACGCAGCGCGGACCCC
Reverse GGGGTCCGCGCTGCGTTGGCTGCAGCCCCCCCT
N58Q/N68Q Forward GCCGACCTCGGCTACCAAGGCACCCGCCAAA
GGGGGGGCTGCAGCCAACGCAGCGCGGACCCC
Reverse GGGGTCCGCGCTGCGTTGGCTGCAGCCCCC
CCTTTGGCGGGTGCCTTGGTAGCCGAGGTCGGC
N-terminal HA tag Forward TCAAGATCTCACCATGTACCCATACGATGTTCCA
GATTACGCTATGGAGGGGCGCGTGAGC
Reverse TATAGATCTCAGGGGCTCTGGGGAAACTG
C-terminal HA tag Forward TATAAGCTTCACCATGGAGGGGAGCGCGAGC
Reverse TCATCTAGATTAAGCGTAATCTGGAACATCG
TATGGGTAGGGCTCTGGGGAAACTGtrypsinized and passaged into 100 mm culture plates at appropriate densities and
allowed to grow in RPMI-1640media containing 800 µg/mL of G418 sulfate (Mediatech,
Herndon, VA). Individual clones were isolated, expanded and maintained in the same
medium supplemented with 800 µg/mL of G418. Several (N20) clones expressing the
desired N- and C-terminus tagged wild-type and N58Q/N68Q-HsPCFT were screened
and one clone of each construct with the highest activity was selected for further
analysis. HeLa cells were transfected with empty pcDNA3.1(+) vector (mock) or the
same vector containing wild-type or mutant HsPCFT. [3H]MTX inﬂux was then assessed
at pH 5.5.
2.5. PNGaseF and EndoH treatment
Enzymatic deglycosylation of total membrane protein (200 µg) prepared (see
Western blot analysis below) from HsPCFT cDNA-transfected HeLa cells was performed
with PNGaseF enzyme (Sigma, G5166) following the manufacturer's protocol. Because
heat denaturation was omitted, the incubation time of the protein sample in 250 mM
phosphate buffer (pH 7.5) and 2.5 µL of 2% SDS with 1 M 2-mercaptoethanol was
increased to 1 h at room temperature. Cleavage of the asparagine-N-acetyl glucosamine
bond was monitored by SDS-PAGE. Membrane preparations were treated with EndoH
(Roche Diagnostics, Mannheim, Germany) following the manufacturer's protocol.
RNaseB (New England Biolabs) was treated under the same conditions as a control for
EndoH activity.
2.6. Tunicamycin treatment
Tunicamycin (T7765)(Sigma, St. Louis, MI) was dissolved in DMSO and added to
growth medium to achieve concentrations of 0.25, 0.5, 1 µg/mL at the same time the
cells were transfected with HsPCFT cDNA. Tunicamycin remained in the growth
medium for 48 h when the cells were assayed.
2.7. Membrane transport measurements
Cells were seeded in 17 mm glass scintillation vials to a ﬁnal density of 4×105 cells/
mL. When cells reached mid-log phase growth ~72 h later, as determined
microscopically, uptake determinations were performed [21]. Brieﬂy, the media was
aspirated and the cells incubated with HEPES Buffered Saline (HBS) (20 mM HEPES,
5 mM dextrose, 140 mM NaCl, 5 mM KCl, 2 mMMgCl2, at pH 7.4) for 20 min. To initiate
uptake, HBS was removed,MES buffered saline (MBS) (20mMMES,140mMNaCl, 5 mM
KCl, 2 mM MgCl2, 5 mM dextrose, at pH 5.5) containing [3H]MTX (0.5 μM, speciﬁc
activity 1000–2000 dpm/pmol) was added to the cells. Uptake was stopped by placing
the vial in ice followed by rapid but careful addition of 6 mL of ice-cold HBS (pH 7.4).
After three washes, cells were lysed with 0.5 mL of 0.2 N NaOH at 65 °C for 30 min;
400 μL of lysate was used to determine radioactivity in a liquid scintillation
spectrometer. Total protein for each sample was determined on a 20 μL portion of the
lysate by the BCA protein assay reagent kit (Pierce, Rockford, IL). Data is expressed as
pmol MTX/vial and normalized to total protein (pmol/mg protein).
2.8. Western blot analysis
Conﬂuent HeLa cells in 17-mm glass scintillation vials were washed twice with ice-
cold PBS and the cells were scraped off with PBS containing Roche protease inhibitor. To
obtain total membrane fractions, cells were incubated on ice for 30 min in hypotonic
buffer (200 µL/106 cells) (0.5 mMNa2HPO4, 0.1 mM EDTA at pH 7.4) containing protease
inhibitor, following which the membrane fraction was pelleted by centrifugation at
14,000 ×g and 4 °C for 2 min. The pellet was resuspended in lysis buffer (100 µL/106
cells; 20 mM TRIS-base, 150 mM NaCl, 1% Triton X-100, 0.1% SDS, 1 mM EDTA at pH 7.4)
and brieﬂy sonicated with the Microson XL 2000 ultrasonic liquid processor (Misonix
Incorporated, Farmingdale, NY) and protein was determined as indicated above.
Proteins were dissolved in SDS-PAGE loading buffer (0.225 M Tris.Cl [pH 6.8], 50%
glycerol, 5% SDS, 0.05% bromphenol blue) with or without 0.25 M dithiothreitol (DTT).
Portions of the preparation were then subjected to a 10 min incubation at room
temperature, 50 °C, 75 °C or 95 °C followingwhich proteins were resolved on a 12% SDS-
polyacrylamide gel. The proteins were then transferred to PVDF Transfer Membranes
(Amersham Life Science). A polyclonal anti-HsPCFT antibody to the distal C-terminus of
HsPCFT (amino acids 446–459) was used to probe the plasma membrane as previously
described [8]. A rabbit anti-HA antibody (#H6908) obtained from Sigma (St. Louis, MI)
was used to detect HA-tagged proteins. Membranes were processed by the ECL Plus
Western Blotting Detection System (Amersham Life Science).
2.9. Immunoﬂuorescence microscopy
A commercially available Alexa Fluor 488 conjugated anti-HA monoclonal antibody
16B12 (1 mg/mL) obtained from Invitrogen (Carsbad, CA) was used to localize HA-
tagged wild-type and N58Q/N68Q-HsPCFT proteins by direct immunoﬂuorescence.
Stably transfected HeLa cells grown on coverslips were washed ﬁve times with RPMI-
1640 medium and the cells ﬁxed with 1% paraformaldehyde for 30 min at room
temperature. Cells were permeabilized with 0.2% Triton X-100 in PBS for 15 min at RT.
The cells were blocked with 2% bovine serum albumin containing 5% donkey serum
(blocking buffer) for 30 min, then 200 µL of Alexa Fluor 488 conjugated anti-HA
monoclonal antibody solution (1 µL of antibody in 8mL of blocking buffer) was added to
Fig. 2. The effect of heating onWestern blot analysis of HsPCFT. Equal amounts of lysate
(30 µg) were incubated in the loading buffer with DTT at the indicated temperatures for
10 min before loading onto the SDS-gel. The blots were probed with a polyclonal
peptide antibody directed to the C-terminus ofHsPCFT. The numbers on the left indicate
the molecular sizes of protein bands. The blot is representative of three separate
experiments.
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each for 5 min, and coverslips were placed on slides with mounting medium containing
propidium iodide to visualize DNA (Vector, CA). The slides were then sealed and viewed
with an Olympus IX70 Inverted Epiﬂuorescence Microscope (Center Valley, PA) with
488 nm excitation.
2.10. Data analysis
Data presented is the mean±standard error of the mean (SEM) of at least three
independent experiments. Statistical comparisons were performed by the two-tailed
Student's paired t-test. Some experiments were assessed using a one-way repeated
measures analysis of variance (ANOVA) and the Tukey's post test. All statistical
analyses were performed using GraphPad PRISM (version 3.0 for Windows, GraphPad
Software).
3. Results
3.1. Computational analysis of the HsPCFT protein sequence
HsPCFT protein (NP_542400) consists of 459 amino acids with a
predicted molecular weight (MW) of ~50 kDa (http://ca.expasy.org/
tools/protparam.html). HsPCFT is a basic protein, with a predicted pI
of 9.03, highly enriched with hydrophobic residues. The primary
structure of the protein has two putative N-linked glycosylation
consensus sites (http://www.cbs.dtu.dk/services/NetNGlyc) at posi-
tions Asn58 (N-G-T) and Asn68 (N-R-S), as illustrated in Fig. 1. These
sites are predicted to be within the extracellular loop between TMDs I
and II (HMMTOP, PredictProtein, TMpred, TopPred analyses). The
glycosylation consensus sites (N-X-S/T) are highly conserved among
species [Macaca mulatta (XP_001106954),Mus musculus (NP_081016),
Bos taurus (NP_001073053), Xenopus laevis (AAH77859), Danio rerio
(NP_956579), Monodelphis domestica (XP_001375817), Rattus norve-
gicus (NP_001013991), Canis familiaris (XP_548286)] (http://www.ebi.
ac.uk/clustalw/).
3.2. The effect of temperature on HsPCFT protein stability
When membrane samples were heated for 5–20 min at 95 °C to
denature the protein in preparation for SDS-PAGE, as is the conven-
tional method [22–24], no protein was detected likely due to HsPCFT
aggregation and immobilization in the stacking gel. To establish con-Fig. 1. A membrane topology model for HsPCFT predicted by online databases (http://www
glycosylation consensus sites (arrows).ditions that obviate aggregation, plasma membrane protein fractions
were prepared from HeLa cells 48 h after transfection with HsPCFT
cDNA, then incubated in the loading buffer containing SDS with and
without DTT at RT, 50 °C, 75 °C or 95 °C for 10 min before PAGE. When
incubated in SDS solution at RT or 50 °C, protein migrated as three
bands: (i) a broad band centered at ~55 kDa, (ii) a smaller band at
~47.2 kDa, and (iii) the narrowest band at ~35.1 kDa. But there was no
detectable protein on the separating gel when it was heated above
50 °C (Fig. 2). HsPCFT proteinwas detected in stacking gels but not the
separating gelwhen the samplewas heated at 75 °C and 95 °C (data not
shown). Based on these observations, membrane fractions were main-
tainedon iceor roomtemperature in the loadingbufferprior toSDS-PAGE.
3.3. Assessment of N-linked glycosylation with PNGaseF and EndoH
The molecular size of the HsPCFT protein detected in HeLa cells,
~55 kDa, was higher than the predicted molecular weight of ~50 kDa
[8]. As indicated above, there are two predicted N-linked glycosyla-
tion sites in the ﬁrst extracellular loop of HsPCFT. To determine if this
size discrepancy is due to post-translational glycosylation at these
sites, membranes from HeLa cells transiently transfected with HsPCFT.expasy.org/tools/#topology) and the locations of asparagine residues in the N-linked
Fig. 4. The effect of tunicamycin treatment on the transport function (upper panel) and
the apparent molecular size (lower panel) of HsPCFT. Upper panel; [3H]MTX inﬂux in
Hela cells transiently transfected with HsPCFT cDNA and treated with tunicamycin.
Uptake of 0.5 µM [3H]MTX was assessed at pH 5.5 and 37 °C over 2 min in HeLa cells
grown in the absence or presence of tunicamycin for 48 h. The transport activity in
control cells is 214.0±30.2 pmol/mg/2 min. The p value reﬂects the comparison of the
difference between control cells and cells treated with 1 μg/mL tunicamycin. Data are the
mean±SEM from three independent experiments. Lower panel; Western blot analysis of
HsPCFT protein after tunicamycin treatment of HeLa cells. Equal amounts of lysate
(30 µg) from HeLa cells, grown in the presence of increasing tunicamycin concentrations
were loaded and the blotswere probedwith a peptide antibody directed to the C-terminus
ofHsPCFT. The numbers on the left indicate themolecular sizes in the protein ladders. The
blot is representative of three separate experiments.
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the ﬁrst N-acetyl glucosamine of both complex and high mannose
oligosaccharides and the asparagine residue in the canonical
consensus sequence [25]. Untreated protein displayed the above-
noted three bands: a broad band centered at ~55 kDa and two other
smaller bands detected at ~47.2 kDa and ~35.1 kDa. When protein
samples were treated with PNGaseF, virtually all protein migrated at a
molecular weight of ~35.1 kDa with only very low levels of higher
MW bands that likely represent incomplete PNGaseF reaction
products (Fig. 3). Membrane protein fractions of HeLa cells transiently
transfected with HsPCFT were also treated with EndoH [26]. There
was no detectable change in the Western blot. This was unlike the
results with RNaseB, an established substrate for EndoH, in which
there was an expected gel-shift upon similar treatment with this
enzyme (data not shown).
3.4. Assessment of N-linked glycosylation in intact HeLa cells with
tunicamycin
Another approach was utilized to assess glycosylation of HsPCFT
based on inhibition of de novo N-linked glycosylation by tunicamycin
[27]. HeLa cells transiently transfected withHsPCFTcDNAwere exposed
to a spectrum of tunicamycin concentrations for 48 h following which
crude plasmamembranes were prepared and subjected toWestern blot
analysis. As indicated in Fig. 4 (lower panel), high molecular weight
HsPCFTbands decrease as the tunicamycin concentrationwas increased;
this was accompanied by an increase in the ~35 kDa band. By 1.0 µg/mL
tunicamycin, the only band present was at 35.1 kDa. Studies were also
undertaken to determine the impact of tunicamycin inhibition of
HsPCFT glycosylation on transport function in HeLa cells. There was no
signiﬁcant effect of low levels of tunicamycin on [3H]MTX inﬂux (Fig. 4,
upper panel) and the small decrease (~22%) observed at 1 μM drug,
when glycosylation was completely inhibited, was not statistically
signiﬁcant (p=0.09).
3.5. Site-directed mutagenesis of N-linked glycosylation sites
To further verify the N-linked glycosylation sites and their
functional importance, three different site-directed mutants of
HsPCFT were constructed at the putative N-glycosylation sites. The
asparagine residues at Asn58 and Asn68were replaced either singly or
together by a glutamine residue to yield the Asn58Gln (N58Q-
HsPCFT), Asn68Gln (N68Q-HsPCFT) single mutants and the N58Q/
N68Q-HsPCF double mutant. To assess the functional consequences of
these mutations, wild-type HsPCFT and the mutant constructs were
transiently expressed in HeLa cells and inﬂux of 0.5 µM [3H]MTX wasFig. 3. The effect of PNGaseF treatment on the apparent molecular size of HsPCFT.
In vitro enzymatic deglycosylation was achieved by addition of PNGaseF (10 U/mL) to
200 µg of membrane protein with incubation for 3 h at 37 °C. An equal amount of
PNGaseF treated (right lane) and control (left lane) lysate (30 µg) was loaded and the
blots were probed with a peptide antibody directed to the C-terminus of HsPCFT.
Numbers on the left indicate the molecular sizes in the protein ladders. The blot is
representative of three separate experiments.assessed. As shown in Fig. 5 (upper panel), inﬂux in the N58Q-HsPCFT
and N68Q-HsPCFT single mutant transfectants was 79–83% of the
transport rate detected in wild-type HsPCFT cDNA-transfected cells
(pN0.05). [3H]MTX inﬂux was decreased by 40% in the double mutant
(p=0.05).
Immunoblots of the crude plasmamembranes prepared fromHeLa
cells transiently transfected with HsPCFT cDNA, using anti-HsPCFT
antibody, showed wild-type HsPCFT protein running at an apparent
molecular weight of ~55 kDa, Asn58Gln/Asn68Gln-HsPCFT protein
running at a molecular weight of ~35 kDa, and both N58Q-HsPCFT and
N68Q-HsPCFT with a predominant band at an apparent molecular
weight of ~47 kDa, a size intermediate between that of the wild-type
and the double mutant HsPCFT (Fig. 5, lower panel). Hence, both
Asn58 and Asn68 residues were glycosylated, and produced a similar
alteration in the migration pattern of the protein on SDS-PAGE. These
observations conﬁrm that the ~35 kDa band represents deglycosy-
lated HsPCFT.
3.6. Analysis of the structural integrity of C- or N-terminus hemagglutinin
(HA) tagged wild-type and deglycosylated (Asn58Gln/Asn68Gln) HsPCFT
mutants in HeLa cells
The migration pattern observed by deglycosylation of HsPCFT
in vitro with PNGaseF, after inhibition of N-linked glycosylation in
intact cells with tunicamycin or by site-directed mutagenesis, all
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evaluate the possibility that this was due to proteolytic degradation,
wild-type and N58Q/N68Q-HsPCFT, HA-tagged at either the N- or C-
terminus, were transiently transfected into HeLa cells andWestern blot
analysis was performed with anti-HA antibody. The HA tag at either
terminus did not affect the function of the wild-type HsPCFT or the
deglycosylated mutant (Fig. 6, upper panel). When probed with anti-
HA antibody, both N- or C-terminus HA-tagged wild-type HsPCFT
migrated predominantly to a mean molecular size of ~55 kDa with a
smaller band at ~47 kDa. Both N- or C-terminal HA-tagged N58Q/
N68Q-HsPCFT migrated at a single band at a MW of ~35 kDa (Fig. 6,
lower panel). These data exclude proteolytic degradation of wild-
type or deglycosylated forms of HsPCFT as a basis for the lower than
predicted molecular size observed on Western blot. Hence, the
anomalous migration of the HsPCFT protein on SDS-PAGE appears to
be an intrinsic characteristic of the protein under these conditions.
3.7. Localization of the wild-type and deglycosylated HsPCFT proteins HA
tagged at the amino or carboxyl terminus
Localization of the wild-type and N58Q/N68Q-HsPCFT, stable trans-
fectants with high level expression of either the N- or C-terminus
HA-epitope tag was assayed by immunoﬂuorescence stainingwith orFig. 6. The effect of HA tagging on the transport function (upper panel) andmolecular size
(lower panel) of thewild-type and deglycosylated (N58Q/N68Q) HsPCFT. Upper panel;
[3H]MTX inﬂux in HeLa cells transiently transfected with cDNAs of N- or C-terminus HA-
taggedwild-type andN58Q/N68Q-HsPCFTmutant (degly-HsPCFT). Inﬂuxof 0.5µM[3H]MTX
was assessed at pH 5.5 and 37 °C over 2 min. Transport activity inwild-type transfectants is
288.8±12.6 pmol/mg/2 min. The p value reﬂects the difference in activity between the
wild-type and deglycosylated HsPCFT. Data are the mean±SEM from three indepen-
dent experiments. Lower panel; Western blot analysis of membrane proteins from
HeLa cells transiently transfectedwith wild-type or deglycosylated HsPCFT fusedwith
an HA epitope on either the N- or C-terminus. An equal amount of lysate (20 µg) was
loaded and the blots were probed with a monoclonal anti-HA antibody. The numbers
on the left indicate the molecular sizes in the protein ladders. Each blot is
representative of three separate experiments.
Fig. 5. The transport function (upper panel) and molecular size (lower panel) of N58Q-,
N68Q- and N58Q/N68Q-HsPCFT mutants. Upper panel; [3H]MTX inﬂux in HeLa cells
transiently transfected with wild-type HsPCFT or glycosylation mutants. Uptake of
0.5 µM [3H]MTXwas assessed at pH 5.5 and 37 °C over 2 min. Transport activity inwild-
type transfectants is 155.3±36.4 pmol/mg/2 min. The p value reﬂects the difference in
activities of the mutant as compared to the wild-type HsPCFT transfectants. Data are
the mean±SEM from three independent experiments. Lower panel; Western blot
analysis of wild-type and glycosylation mutant HsPCFT membrane proteins. An equal
amount of lysate (20 µg) was loaded and the blots were probed with a peptide antibody
directed to the C-terminus of HsPCFT. The numbers shown on the left side indicate the
molecular sizes in the protein ladders. The blot is representative of three separate
experiments.without membrane permeabilization. As indicated in Fig. 7, ﬂuores-
cence was detected in all permeabilized cells with the exception of
mock transfected cells. No ﬂuorescence could be detected in cells that
were not permeabilized. Hence, both wild-type and deglycosylated
HsPCFT proteins localized to the plasma membrane and both N-
and C-termini were accessible to the antibody only when cells were
permeabilized under these conditions. These data are consistent
with a cytosolic localization for both the N- and C-terminus and
indicates that the lack of N-glycosylation has little or no effect on
HsPCFT membrane targeting.
4. Discussion
HsPCFT is a recently discovered carrier protein that mediates
intestinal folate absorption and transport of folates into the central
nervous system [8]. HsPCFT is expressed in other tissues as well and a
low-pH folate transport activity, presumably HsPCFT, is present in
most human solid tumors and likely contributes to transport of folates
in these settings [8,14]. The murine ortholog of HsPCFT was reported
to be a heme carrier protein, (HCP-1, SLC46A1), responsible for
intestinal heme absorption that functions independent of pH (over a
Fig. 7. Immunoﬂuorescence staining of wild-type and deglycosylated HsPCFT. HeLa cells were stably transfected with cDNA of wild-type or deglycosylated HsPCFT fused with the HA
epitope on either the N- or C-terminus, then exposed to Alexa Fluor 488 conjugated anti-HA monoclonal antibody. Green ﬂuorescence indicates localization of HsPCFT, while red
ﬂuorescence indicates nucleic acids counterstained by propidium iodide. The image is representative of at least three experiments. The left panel shows cells subjected to
permeabilization with Triton X-100 before exposure to antibody. The right panel shows cells that were not permeabilized.
1412 E.S. Unal et al. / Biochimica et Biophysica Acta 1778 (2008) 1407–1414pH range of from 6.5 to 8.0) and with a low afﬁnity for heme
(Km=125 μM for [55Fe]hemin) [28]. However, in studies from this
laboratory [8], and in a recent report from another laboratory [29], it is
clear that this is a high-afﬁnity folate transporter (inﬂux Km's in the
range of 0.2–1.0 µM)with a low-pH optimum. Additional conﬁrmation
that the major, if not sole, function of this carrier is folate transport
comes from the observation that loss-of-function mutations in
HsPCFT result in an autosomal recessive disorder, hereditary folate
malabsorption. Individuals with this disorder show no evidence of
iron deﬁciency and the metabolic consequences of the transport
defect can be corrected solely by the administration of pharmacolo-
gical doses of folate [8,9].
The data indicate that HsPCFT is highly heat labile; at temperatures
above 50 °C the protein aggregates, a condition that must be
considered in the preparation of cell membranes for SDS-PAGE. The
basis for this aggregation is not clear but may be due to the properties
of speciﬁc hydrophobic regions of the carrier as reported for SARS-CoV
membrane protein [30]. On SDS-PAGE the wild-type protein ran as
three bands at ~55 kDa, ~47.2 kDa and ~35.1 kDa. The three
independent approaches used to assess HsPCFT glycosylation statusyielded a deglycosylated protein with an apparent molecular size of
~35 kDa, 15 kDa smaller than the predicted size for nonglycosylated
HsPCFT (~50 kDa). Further studies using HsPCFT HA tagged on the N-
and C-termini excluded the possibility that this discrepancy is due to
degradation of the protein. This anomalous electrophoretic behaviour
is quite common among polytopic membrane proteins and is similar
to what has been reported for the human norepinephrine [31] and
glycine transporters [32]. This could be due to (i) the highly
hydrophobic nature and basic pI of the transporter [33] and/or, (ii)
preservation of the native, compact conformation and decreased SDS
binding due to the heating limitation resulting in incomplete
denaturation of the HsPCFT protein [34,35]. Decreased SDS binding
may decrease the migration rate by reducing the net charge;
alternatively, it may increase the migration rate by reducing the
mass and frictional drag. The intact disulﬁde bonds, which usually
result in less SDS binding of a more compact shaped protein, can also
cause faster migration rates [36]. However, there was no difference in
the HsPCFT migration pattern when membranes were prepared with
or without DTT before loading onto the gel. Replacement of the seven
native cysteine residues with serines had no effect on HsPCFT function;
1413E.S. Unal et al. / Biochimica et Biophysica Acta 1778 (2008) 1407–1414hence, disulﬁde bonds are not required for proper HsPCFT folding and
function (Unal ES et al., unpublished).
Glycosylation on asparagine 58 and 68 conﬁrms that the ﬁrst
methionine is the actual translation initiation site since the second
methionine in the amino acid sequence ofHsPCFT is at the 75th position
after the glycosylation consensus sites. The results suggest that an
approximately 20 kDa oligosaccharide chain is added to HsPCFT when
expressed in HeLa cells based upon the size of glycosylated HsPCFT
(~55 kDa) and deglycosylated transporters (~35 kDa). It is of interest that
HsPCFTmay be glycosylated to a different extent in different cells. Hence,
~60 kDa and ~78 kDa sizeHsPCFT proteins were detected in HepG2 cells
andXenopusoocytes, respectively [8]. Further studies on theglycosylation
status of HsPCFT from native tissues, and their effect on the migration
pattern relative to what is observed in Hela cells, will be of interest.
Similar to most membrane transporters that are N-linked glycosy-
lated on a single large extracellular loop [37], post-translational modi-
ﬁcation ofHsPCFTbyN-linked glycosylation atN58 andN68 requires the
extracellular localization of this domain, since oligosaccharide chains are
transferred en bloc from a dolichol donor to the nascent polypeptide
simultaneously with translation only if the NXS/T consensus site faces
the endoplasmic reticulum lumen [38]. This is consistent with a
topologicalmodel inwhich theN-terminus is localized to the cytoplasm.
This conﬁguration was supported by immunocytochemical analysis of
both wild-type and deglycosylated HsPCFT constructs HA tagged at the
amino terminus, visualized at the plasma membrane only when cells
were ﬁrst permeabilized with Triton X100 [39–42]. This data also
supports a model in which there is an even number of transmembrane
domains, requiring that theC-terminus is also localized to the cytoplasm.
Hence,wild-typeanddeglycosylatedHsPCFT,HAtaggedat theC-terminus,
could only be detected after membrane permeabilization.
N-linked glycosylation is not essential for cell surface trafﬁcking and
functionofRFC [43] and the creatine transporter [44]. On theotherhand,
N-linked glycosylation can play a role in proper folding of the poly-
peptide chain, protection from proteolytic degradation [45], main-
tenance of protein solubility [46] and targeting to subcellular
compartments and to the cell surface [47]. The latter roleof glycosylation
has been reported for many transporters such as the human
norepinephrine [31], glycine (GLYT1) [32], glucose (GLUT1) [48], organic
anion (OAT4) [47] andorganic cation transporters [49]. In these cases the
transport proteins are heavily glycosylated on three or more asparagine
residues and the deglycosylated protein retains only a small percentage
of wild-type activity. In contrast, HsPCFT is glycosylated only on
asparagine 58 and 68 and the majority of HsPCFT transport function
was preserved in the N58Q/N68Q-HsPCFT mutant. Indeed, the small
decrease observed could be due to the amino acid changes per se rather
than the absence of glycosyl moieties since, at a tunicamycin con-
centration sufﬁcient to completely abolish glycosylation, no signiﬁcant
decrease in HsPCFT function could be detected.
N-linked glycosylation scanning mutagenesis is a useful technique
to analyze the topology of various transporters [32,50]. The pre-
requisite for this approach is a functional deglycosylated transporter
[51]. The observation that the majority of function is preserved in
deglycosylated HsPCFT indicates that glycosylation scanning muta-
genesis can be used to further evaluate the secondary structure of this
carrier and that bacterial systems can be used to produce large
quantities of this transporter for structural studies.
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